- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Brett McQueen on Taking Into Account Nontraditional Criteria for Determining Cost Effectiveness
R. Brett McQueen, PhD, assistant professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need to account a myriad of criteria when determining cost effectiveness.
R. Brett McQueen, PhD, assistant professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need to account a myriad of criteria when determining cost effectiveness.
Transcript
When determining the cost-effectiveness or other value metrics, why is it important to have decision making that takes into account a myriad of criteria?
Taking into account not only traditional criteria, such as cost-effectiveness or comparative effectiveness, but also nontraditional criteria, such as novel mechanism of action, can help align incentives across multiple stakeholders, so it’s very beneficial in merging the discussion around stakeholders.
How does multiple-criteria decision analysis add value and transparency to current commonly used techniques for decision making?
Coverage and reimbursement decision making will always involve some form of deliberation. There’s no getting around that. But, MCDA [multiple-criteria decision analysis] can help form a structure for that deliberation, and even quantify that deliberation, and that really can help incentivize stakeholders to join in and have a transparent and open discussion about value.
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS
April 11th 2025Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora
March 26th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Read More
